Skip to main content

Table 3 Changes in serum adipokines during the study

From: Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

  M0 (N = 107) M1 (N = 106) M3 (N = 104) M6 (N = 97) M12 (N = 77) P*, M0 vs M6 (N = 97) P*, M0 vs M12 (N = 77) P#
Total adiponectin (μg/mL) 14.54 ± 8.1 15.5 ± 8.7 15.7 ± 9.9 14.6 ± 7.5 14.2 ± 7.6 0.055 0.25 0.3
Total adiponectin (μg/mL), TCZ alone 15.18 ± 7.8 14.75 ± 7.9 14.76 ± 6.6 15.03 ± 7.5 14.23 ± 6.6 0.34 0.8 0.31
Total Adiponectin (μg/mL), TCZ and csDMARDs 14.40 ± 8.3 15.82 ± 9.1 16.04 ± 11.0 14.47 ± 7.6 14.14 ± 8.2 0.1 0.24 0.019
HMW adiponectin (μg/mL) 7.3 ± 5.4 8.3 ± 6.6 8 ± 6.4 7.5 ± 5,4 6.8 ± 4.6 0.011 0.057 0.01
HMW adiponectin (μg/mL), TCZ alone 7.32 ± 4.50 7.87 ± 5.40 7.94 ± 5.22 7.97 ± 5.21 7.03 ± 4.72 0.052 0.046 0.09
HMW adiponectin (μg/mL), TCZ and csDMARDs 7.07 ± 5.28 8.42 ± 7.08 8.06 ± 6.84 7.32 ± 5.47 6.73 ± 4.66 0.045 0.3 0.045
Leptin (ng/mL) 32.64 ± 26.9 32.45 ± 25.4 31.7 ± 23.6 32.6 ± 27.3 32.8 ± 27.5 0.059 0.17 0.22
Leptin/fat mass 1.08 ± 0.7 ND ND 1.1 ± 0.8 1.2 ± 1.4 0.049 0.2 0.14
Resistin (ng/mL) 10.5 ± 4.9 11 ± 4.9 10.9 ± 4.6 10.8 ± 4,9 10.9 ± 5.3 0.53 0.16 0.13
Ghrelin (pg/mL) 2121.9 ± 1309.4 2031.5 ± 1266 2072.9 ± 1299 2074.8 ± 1278.4 2035 ± 1304.3 0.78 0.19 0.28
  1. Results are given as mean ± SD
  2. M month, TCZ tocilizumab, HMW high molecular weight, ND not determined
  3. *Paired Student’s t test
  4. #Sensitivity analysis
\